Related Experiment Video
Updated: Oct 27, 2025
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
Published on: November 30, 2022
"Impact of pentaglobin in severe COVID 19 pneumonia- a prospective study."
Dinesh Joshi1, Kamal Sharma1, Senthilraj Thangasami1
1Department of Cardiology U. N. Mehta Institute of Cardiology and Research Centre (UNMICRC), Civil Hospital Campus, Asarwa, Ahmedabad, Gujarat 380016, India.
Insights
Pentaglobin, an intravenous immunoglobulin, did not significantly improve outcomes for severe COVID-19 pneumonia patients. This study found no added benefit in reducing hospital stay, mechanical ventilation, or mortality compared to standard care.
Area of Science:
- Immunology
- Critical Care Medicine
- Infectious Diseases
Background:
- The COVID-19 pandemic created a critical need for effective treatments for severe pneumonia.
- Investigating novel therapeutic options like Pentaglobin is crucial for managing severe COVID-19 cases.
Purpose of the Study:
- To evaluate the effectiveness of Pentaglobin as an adjunct therapy for severe COVID-19 pneumonia.
- To determine if Pentaglobin reduces disease severity, hospital stay, or mortality.
Main Methods:
- An open-label, non-randomized controlled study compared Pentaglobin plus standard therapy (n=17) against standard therapy alone (n=19).
- Severity was assessed using clinical scores and inflammatory markers.
- Outcomes included hospital stay duration, need for invasive ventilation, and mortality.
Main Results:
- Pentaglobin did not significantly reduce the average length of hospital stay (12.35 vs. 10.94 days, p=0.4).
- No significant differences were observed in the requirement for invasive ventilation (p=0.56) or mortality (p=0.86) between groups.
- CT Severity, APACHE II, and SOFA scores were identified as independent predictors of mortality.
Conclusions:
- Pentaglobin administration showed no significant effect in reducing mechanical ventilation risk or mortality in COVID-19 patients.
- The study did not find Pentaglobin beneficial for disease worsening or inflammation reduction in this patient group.
Background:
The current COVID-19 pandemic has become a global public health crisis and presents a serious challenge in treatment of severe COVID pneumonia patients. With an imperative need for an effective treatment, we aimed to study the effectiveness of Pentaglobin, an intravenous immunoglobin in the treatment of severe Covid-19 pneumonia patients.
Methods:
This is an open-label non-randomised controlled study. Patients in the study group (n = 17) received Pentaglobin in addition to standard therapy and the control group (n = 19) received only the standard of care treatment. Severity of illness were quantified by severity scores and inflammatory laboratory parameters were compared between the two groups.
Results:
The average length of hospital stay in pentaglobin group were 12.35 ± 6.98 days compared to 10.94 ± 4.62 days in standard treatment group with mean difference of 1.4 days (p value = 0.4). Pentaglobin did not provide an added advantage in terms of reducing the duration of hospital stay. There was no significant difference between both the groups in terms of requirement of invasive ventilation (p = 0.56) and mortality (p = 0.86). CT Severity score (OR = 1.39 95% CI = 1.09-1.77, P = 0.01), APACHE II score (OR = 1.16 95% CI = 0.99-1.35, P = 0.05) and the SOFA score (OR = 2.11 95% CI = 1.13-3.93, P = 0.02) were independent predictors of mortality.
Conclusion:
The administration of pentaglobin in COVID -19 patients has no significant effect in reducing the risk of mechanical ventilation or death, in disease worsening or in reduction of inflammation.
More Related Videos
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
01:29Pneumonia II: Pathophysiology
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia III: Complications and Assessment
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....